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Intensiﬁcationel of total viral DNA in HIV-infected patients, but few studies report the level of
integrated DNA. It is important to measure integrated DNA in HIV-infected patients because the information
could shed light on the effectiveness of antiretroviral therapy, especially intensiﬁed therapy, when viral loads
may remain undetectable. In order to develop an integration assay for patient samples, we enhanced the
sensitivity of our prior integration assay. To do this, we exploited a technique that we developed, called
repetitive sampling, and optimized reaction conditions for rare event detection, rather than large dynamic
range. We also designed our primers to match more conserved regions of HIV. The result is a new, sensitive,
quantitative assay that allows us to measure integrated DNA in HIV-infected patients. When we applied our
integration assay to patient PBMCs, we found that the use of HAART is associated with reduced levels of
integrated DNA.
© 2008 Elsevier Inc. All rights reserved.Introduction
Integration is a central step in the HIV life cycle: it is required for
efﬁcient transcription of the genome, for replication, and for
establishment of reservoirs. Given that integration is essential for
viral survival in the host, it is important to monitor the level of
integrated DNA. In addition, unintegrated DNA is only transcribed at
low levels (Brussel and Sonigo, 2004; Nakajima et al., 2001; Wu and
Marsh, 2001, 2003a, 2003b), and is likely to contribute little to
productive HIV infection (Nakajima et al., 2001). Thus, it may be
important to distinguish between integrated an unintegrated HIV
DNA. However, measuring integration accurately in patient samples is
difﬁcult for two reasons. First, in HIV-infected individuals, uninte-
grated DNA is present in excess over integrated DNA and so routine
PCR does not distinguish unintegrated from integrated DNA. Second,
the level of integration in HIV-infected individuals is low andherty).
l rights reserved.detection is a further challenge since only a fraction of integration
events are detectable because of the widely distributed integration
sites (Agosto et al., 2007). While many studies have reported the level
of total viral DNA in cells from HIV-infected individuals (Brenchley et
al., 2004; Burgard et al., 2000; Debiaggi et al., 2000; Douek et al.,
2002; Gibellini et al., 2004; Jubault et al., 1998; Kabamba-Mukadi et
al., 2005; Kostrikis et al., 2002; Lillo et al., 2004; Ngo-Giang-Huong et
al., 2001; Rouzioux et al., 2005; Viard et al., 2004; Vitone et al., 2005),
only a few have reported the level of integrated DNA (Carr et al., 2007;
Chun et al., 1995, 1997a, 1997b; Ibanez et al., 1999; Izopet et al., 2002;
Koelsch et al., 2008; Ostrowski et al., 1999).
Currently there are three PCR assays that measure HIV integration:
linker ligation (Vandegraaff et al., 2001), inverse PCR (Chun et al.,
1997a), and Alu-PCR (Brussel et al., 2005; Brussel and Sonigo, 2003;
Butler et al., 2001; O’Doherty et al., 2002). Both endpoint and kinetic
PCR methods have been applied to these assays, and both methods
have their advantages: endpoint PCR is usually more sensitive and
kinetic PCR provides superior quantitation. Studies using endpoint
PCR integration assays (Chun et al., 1995, 1997a, 1997b, 1998;
Table 1
Increasing the number of cycles in the ﬁrst PCR reaction enhanced the sensitivity of the
integration assay
Cycles Alu-gag Ct gag Ct Δ P-value
20 22.6 28.3 5.66 0.005
30 20.5 27.0 6.50 0.005
40 18.7 26.1 7.41 b0.001
The integration standard was diluted to 20 proviruses in 15,000 cells and then assayed
repetitively with 20, 30 or 40 cycles, while the amount of enzyme, extension time and
other variables were kept constant. The number of cycles performed in the ﬁrst PCR
reaction, the average Alu-gag and gag-only signals, as captured by cycle thresholds (Ct),
and the difference between the signals (Δ) are shown. Indicated P-values compare the
Alu-gag signals to the gag-only signals. Value in bold indicates the condition that gave
the most signiﬁcant difference between Alu-gag and gag-only signals.
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resting CD4+ T cells contain integrated DNA and contribute to viral
reservoirs (Chun et al., 1995, 1997a). However, the major limitations of
end point PCR are that it is too labor intensive for the high throughput
needed for clinical samples, and it provides poor quantitation. For
example, two studies using endpoint PCR assays to compare
integration levels in total PBMCs from patients on and off highly
active antiretroviral therapy (HAART) reported conﬂicting results
(Ibanez et al., 1999; Izopet et al., 2002). The conﬂicting results were in
part related to the wide uncertainty in early estimates of HIV
integration because the variation caused by sampling rare events
was not addressed. An additional source of error in the measurements
may have come from false positives; unintegrated DNA may have
contributed to the signal.
Many kinetic PCR integration assays have been developed, and
kinetic PCR can control for false positive signals better than endpoint
PCR, as we described by including gag-only controls (Agosto et al.,
2007; O’Doherty et al., 2002). However, none of the kinetic PCR assays
that have been developed to date are sensitive enough to measure
integration in patient samples. For example, a recent study proposed a
kinetic PCR integration assay for clinical use, but the assay did not
detect integration in ~50% of patient PBMCs (Carr et al., 2007). Thus,
integration data was only obtained for half the patients.
Here, we report a kinetic PCR assay, derived from our original two-
step kinetic Alu-PCR integration assay (O’Doherty et al., 2002), that is
sensitive enough to measure HIV integration precisely in PBMC
samples from patients. To do this, we redesigned our primers and
probes to match more conserved regions of the HIV genome and we
incorporated a technique that repetitively samples DNA (Agosto et al.,
2007). However, even with incorporation of the repetitive sampling
technique to patient samples, the assay still lacked the required
sensitivity (unpublished observations). Here we show that we can
further increase the sensitivity of our integration assay by increasing
the number of cycles in the 1st PCR reaction. Previously, we limited the
number of cycles tomaintain a large dynamic range (i.e. to ensure that
substrateswere not limiting). However, in patient samples the proviral
levels are low and dynamic range is small. Under these conditions, a
dramatic increase in sensitivity can be obtained by increasing cycle
numberwithout compromising quantitation.We used this newkinetic
Alu-PCR integration assay to measure proviral levels in PBMCs from
patients on and off HAART. Compared to patients not on HAART, we
found that patients on HAART had signiﬁcantly lower levels of
integrated HIV DNA (P=0.007). Furthermore, we found the level of
integrated DNA was higher than the original estimates in patients off
HAART (Ibanez et al., 1999; Izopet et al., 2002; Koelsch et al., 2008).
Results
Increasing PCR cycle number increases integration assay sensitivity
(Table 1)
Previously we showed that the sensitivity of our standard
integration assay could be enhanced~40-fold by repetitive sampling
(Agosto et al., 2007), but when applied to patient samples, it was still
not sufﬁciently sensitive to measure integration. Although we had
previously optimized our standard integration assay for cycle number,
extension time, and enzyme concentration (O’Doherty et al., 2002;
Swiggard et al., 2005), nowwe set out to increase the sensitivity of our
repetitive sampling-based assay to detect low integration levels.
To determine the optimal PCR conditions at low proviral numbers
we ﬁrst created a low copy number sample by diluting the integration
standard (IS) (Agosto et al., 2007) to 20 proviruses in 15,000 genomes.
We then assayed the diluted standard repetitively while varying cycle
number, enzyme concentration, and extension time. For each condi-
tion, we measured the average Alu-gag cycle threshold, the average
gag-only cycle threshold, and calculated the difference betweenthese values (Table 1). The optimal conditions were deﬁned as those
that gave the greatest difference between the Alu-gag and gag-only
signals.
We found that, by increasing the number of cycles in the ﬁrst PCR
reaction from 20 to 40, we increased the difference between the Alu-
gag and the gag-only signal to a level that was most statistically
signiﬁcant. Under these new conditions, substrates were not limiting
because a dose-response was preserved when we performed serial 2-
fold dilutions of proviruses from 1000 to 62.5 proviruses (not shown).
Consistent with our prior work, the dose-response was lost at higher
concentrations of provirus (between 1000 and 100,000) when
40 cycles of ampliﬁcation were used (not shown). We further
optimized ampliﬁcation conditions by doubling the amount of
enzyme and by increasing the extension time from 2.5 to 3.5 min;
however, the effect of these two modiﬁcations on increasing the
difference between Alu-gag and gag-only signals was small relative to
the effect of increasing the cycle number (not shown).
Design of the primer-probe pair to best match a conserved region of the
HIV genome (Fig. 1)
In order to better match the sequences in the Los Alamos National
Laboratory (LANL) database (Leitner et al., 2005), we redesigned the
primers and probes used in our original assay. To do this, we surveyed
the LANL database for the most conserved regions of the HIV genome.
We slightly modiﬁed the original forward and reverse primers by
shifting their positions relative to the LANL database by 3 and 6
nucleotides, respectively, compared to our original pair (Agosto et al.,
2007). This change resulted in primers that bound to more highly
conserved regions in the HIV genome: the last 3 and 4 nucleotides of
each primer are perfect matches with the database; the remaining
nucleotides are 98–100% conserved (Fig. 1).
Although we were unable to identify a region for the probe that
was as highly conserved, we prepared awild-type probe that has been
previously described (Yun et al., 2002) and two degenerate probes
that were perfect matches for the twomost frequent mutations which
occurr 9% and 4% of the time (Fig. 1). We analyzed between 427 and
627 sequences to determine the frequency of mutations in the primers
and probes. None of the mutations that are shown are linked. These
three probes were mixed in equal concentrations for the kinetic PCR
reaction. When we tested the new primer-probe set and compared it
to the original primer-probe set, we found that both showed near
100% ampliﬁcation efﬁciency, calculated as described (Applied
Biosystems, 2004). In other words, both sets of primers amplify
efﬁciently, but the new set is a better match to patient sequences and
so will pick up more sequences.
Generation of a standard curve using our integration standard (Fig. 2)
Tomimic the low integration frequencies in patient samples and to
determine the sensitivity of our integration assay, we calculated the
Fig. 1. Sequence of the primers and probes used in the HIV integration assay. The
nucleotide sequences and their positions relative to the HIV genome of the forward
primer, reverse primer and probe are shown. The percent identity to the LANL HIV
database consensus is indicated as follows: no symbol denotes 100% identity, an asterisk
(⁎) above a base indicates 99% identity, a circle (○) represents 98% identity, and a
dash (-) indicates 97% identity. The forward primer sits at position 518–539 in the
HIV genome (based on HXB-2 numbering). The reverse primer sits at bases 647–628.
The ﬂuorescent probes lie between 584–559. Two degenerate ﬂuorescent probes
were synthesized to capture the two most mutated bases, highlighted in grey. These
two mutated bases are present in 9% and 4% of sequences. The primer-probe sets
were used to detect either total DNA (without Alu-gag pre-ampliﬁcation) or to detect
Alu-gag amplicons as described in the Methods.
Fig. 2. IS standard curve and linear regression. Alu-gag PCR was performed repetitively
(N=40) on serial 4-fold dilutions of the integration standard. N represents the number
of samples tested. (A) The curves generated at 2.5,10, 40 and 160 proviruses per reaction
are shown for Alu-gag. Background or gag-only signals are not shown, but the brackets
( ) represents the range of gag-only signals. The cycle threshold (Ct) for each sample
was calculated by determining where the PCR curve crosses the horizontal line at 0.01
ﬂuorescence units. (B) The natural log of each Ct for each curve was calculated and then
averaged. A standard curve was then generated by plotting the x-axis as the average of
the natural log of Ct and the y-axis as the natural log of the provirus quantity in the
diluted standard. The provirus number in our integration standard is known as
previously described (Agosto et al., 2007). The error bars represent standard error of the
mean.
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PBMCs as described (Agosto et al., 2007). We calculated the proviral
number in the IS cell line using routine quantitative DNA PCR because
all the HIV DNA in the IS is integrated (Agosto et al., 2007). We
performed Alu-gag ampliﬁcation on IS samples in 40 replicates at
multiple proviral concentrations (Fig. 2A). We consistently assayed
1.5×104 cells per reaction (IS cells+uninfected PBMCs) to maintain a
constant number of Alu sites. We kept the number of Alu sites
constant because we previously determined that the number of Alu
sites per reaction affects the efﬁciency of PCR ampliﬁcation.
We previously showed that our IS contains diverse integration
sites (Agosto et al., 2007; O’Doherty et al., 2002); and because our IS
accurately models integration in vivo, some integration events are
detectable and some are not (Agosto et al., 2007; O’Doherty et al.,
2002). We found that when 160 proviruses per reaction were
assayed repetitively, the Alu-gag signals did not overlap with the
background gag-only signals (Fig. 2A; gag-only curves are not
shown, but brackets denote their location). When 40 proviruses
per reaction were assayed repetitively, although a few Alu-gag
signals overlapped the gag-only signal, the majority of Alu-gag
signals did not (Fig. 2A). As the number of proviruses per reaction
decreased, the fraction of the samples that gave a positive signal
decreased (Fig. 2A).
We determined there was a linear relationship between the
logarithm of the cycle threshold and the logarithm of the proviral
number. For the integration standard, we calculated the natural log of
the cycle threshold (lnCt) and plotted the average of the lnCt against
the natural log of the proviral number (lnn). We observed a linear
relationship between lnn and lnCt (Fig. 2B). This linear relationship is
represented by the equation lnn=D*average(lnCt)+E (Fig. 2B), where
n represents proviral number, Ct represents cycle threshold response,
D=−8.2619, E=29.56, and R2=0.975. Having derived a standard
equation, we could apply it to the results of Alu-gag PCR on patient
samples, and calculate the proviral number in these samples.
Our new integration assay is sufﬁciently sensitive to detect integration in
patient samples (Fig. 3, Table 2)
We wanted to test whether our improved assay was sensitive
enough to measure integration in patient PBMCs. To do this, we
puriﬁed DNA from PBMCs of 10 patients on HAART and 6 patients off
HAART, then performed our new two-step PCR integration assay on 40
samples for each patient repetitively. We obtained a distribution of
Alu-gag ampliﬁcation curves for each patient (Fig. 3, representative
curves). To measure integration levels in patients, we ﬁrst determinedif integrationwas detectable by performing a one-tailed t-test to make
sure that the average Alu-gag was signiﬁcantly lower than average
gag-only. Then, we compared the Alu-gag signals to the Alu-gag
signals generated by our diluted IS samples. We determined the
proviral number for each patient by obtaining the cycle threshold (Ct)
for each Alu-gag ampliﬁcation curve, and taking the natural log of the
cycle threshold (ln(Ct)). Next, we calculated the average ln(Ct) for each
Table 2
Proviral level in patients on and off HAART
HAART Patient Provirus per 104 cells Lower 95% CI Upper 95% CI P-value
ON 1 0.66 0.63 0.70 2×10−02
2 2.9 2.1 4.2 7×10−07
3 2.2 1.5 3.4 1×10−04
4 3.0 2.1 4.4 3×10−03
5 2.5 1.7 3.9 2×10−06
6 0.58 0.49 0.69 2×10−02
7 0.55 0.39 0.78 3×10−05
8 0.43 0.33 0.55 2×10−02
9 3.0 1.5 6.0 3×10−04
10 1.9 1.3 2.6 6×10−05
Average 1.8 1.2 2.7
OFF 11 46 38 54 2×10−40
12 19 15 25 2×10−15
13 9.1 6.8 12 2×10−25
14 6.4 4.5 8.9 2×10−11
15 27 23 32 2×10−13
16 1.5 1.1 2.0 2×10−03
Average 18 15 22
The calculated number of proviruses per 10,000 cells is listed for each patient. In
addition, the upper and lower bounds for 95% conﬁdence intervals are also provided.
The errors are asymmetrical because a logarithmic transformation was performed
before taking averages of the ln (Ct) of the patient samples (as well as the integration
standard). The P-value in the ﬁnal column represents the probability that the Alu-gag
and gag-only signals are not different.
Fig. 3. Representative Alu-gag PCR ampliﬁcation curves. PBMC DNA was prepared from
HIV-infected individuals (Patients 4 and 7 were on HAART and Patients 11 and 14 were
not on HAART). Alu-gag PCR was performed in 40 replicates and then HIV-1 speciﬁc
kinetic PCR was performed on each replicate.
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⁎average (lnCt)+E, where D=−8.26, E=29.56. Lastly, we calculated the
proviral number by taking the exponential of ln(n) and calculated the
95% conﬁdence intervals, which are asymmetric because of the
logarithmic transformation. We found that our improved assay was
sensitive enough to detect proviral loads as low as 0.5 integration
events in 10,000 PBMCs (Table 2, patients 1, 6, 7, and 8). The average
Alu-gag and gag-only signals are provided (Supplemental Table) and
demonstrate that the Alu-gag signal was always signiﬁcantly lower
than the gag-only signal by a one-tailed '’s ">Student’s t-test.
Unintegrated patient DNA does not contribute signiﬁcantly to the
integration assay signal (Fig. 4, Table 3)
DNA extracted from patient PBMCs contains a mixture of HIV DNA
that is integrated into the host chromosome, and HIV DNA that is
unintegrated and present as linear or circular forms. We considered
the possibility that unintegrated HIV DNA may contribute to the Alu-
gag integration assay signal. If this were the case, then our measure-
ments of integrated HIV DNAwould be higher than the actual number
of proviruses.
To determine whether unintegrated DNA contributes to the Alu-
gag signal attributed to integrated DNA, we prepared DNA from
patient PBMCs, separated the chromosomal, linear, and circular
fractions by agarose gel electrophoresis, extracted DNA from the gel,
and performed Alu-gag PCR on individual fractions as well as on a
mixture. When we assayed chromosomal DNA samples, the integra-
tion signal was stronger than the background signal: on average theAlu-gag curves crossed the cycle threshold (Ct) at lower cycle numbers
than the background gag-only curves (Fig. 4, panel A; Table 3, row 1).
By comparison, whenwe assayed linear and circular DNA samples, the
integration signal equaled the background signal: Alu-gag and gag-
only curves crossed the Ct at the same cycle number (Fig. 4, panels B
and C; Table 3, rows 2 and 3). Therefore, HIV integration was detected
only in chromosomal DNA samples. Finally, we found that the Alu-gag
signal from a mixture of the three fractions, was comparable to that
from the chromosomal fraction alone (Fig. 4, compare panel D to A;
Table 3, compare bolded values). Therefore, we conclude that, in a
patient sample containing a mixture of integrated and unintegrated
HIV DNA, unintegrated DNA does not contribute signiﬁcantly to the
Alu-gag signal.
Unintegrated DNA contributes minimally to the integration signal
(Table 4)
In a second approach to determine whether unintegrated HIV
DNA contributes to the Alu-gag signal from integrated DNA, we
modeled the ratio of unintegrated-to-integrated DNA in patient
samples and measured integration. We added 100-fold excess of
unintegrated HIV plasmid DNA (U), NG38, to our integration
standard (IS) DNA, because a 100:1 ratio of unintegrated-to-
integrated DNA was close to the highest ratio that we detected in
patient samples. We found that when we performed Alu-gag and
gag-only PCR on 800 copies of unintegrated DNA (800 U), the Alu-
gag and gag-only signals were equivalent indicating that the sample
was negative for integration (Table 4). When 8 copies of integrated
DNA (8 IS) were assayed, the Alu-gag signal was stronger (detected
at a lower cycle number) than the gag-only signal, indicating that
integration was detected (Table 4). When we added 100-fold excess
of unintegrated DNA to integrated DNA (800 U+8 IS), the Alu-gag
signal remained stronger than the gag-only signal (Table 4). The
Alu-gag signal from 800 U+8 IS was slightly stronger than that from
8 IS (Table 4). This slightly stronger signal translated into only a 2-
fold difference when we calculated the number of proviruses per
well: 7 proviruses/well in the 8 IS sample, 15 proviruses/well in the
800 U+8 IS sample (Table 2). Therefore, we concluded that
unintegrated DNA contributes minimally to the integration assay
signal.
Table 4
Unintegrated HIV plasmid DNA contributes minimally to the Alu-gag signal from an
integration standard
HIV DNA copies
per well
Provirus
per well
Cycle number at which
signal detected
P-value
Alu-gag gag only
800 U 0 27.3 27.3 NS
8 IS 7 29.7 36.4 ≪0.01+
800 U+8 IS 15 25.3 27.3 ≪0.01⁎
Fig. 4. In a patient sample, unintegrated HIV DNA does not contribute signiﬁcantly to the Alu-gag integration assay signal. DNA from patient PBMCs was puriﬁed and size-separated
into three fractions (chromosomal, linear, and circular) by 0.7% agarose gel electrophoresis. Chromosomal DNAwas ~23 kb (due to fragmentation during processing), linear HIV DNA
~9 kb, and circular HIV DNA ~6 kb. The DNA from each fractionwas extracted and resuspended in 100 ml of 10 mM Tris. Alu-gag and gag-only PCR were performed on equal volumes
(8.3 ml) of each fraction separately, and then on a mixture (8.3 ml of each) of the 3 fractions. The Alu-gag and gag-only curves generated from PCR are shown in plots on the right:
panel (A) chromosomal, (B) linear HIV DNA, (C) circular HIV DNA, and (D) mixture of chromosomal, linear, and circular. Alu-gag and gag-only PCR were performed 6 times each on
sample A and 3 times each on samples B–D (due to limited sample). Alu-gag and gag-only signals (Ct) are deﬁned as the cycle number at which a curve crosses the threshold (0.01). A
bracket ( ) indicates the range of signal obtained with gag-only priming. An Alu-gag signal is deﬁned as positive when it is signiﬁcantly different from the gag-only signal by
Student's t-test.
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(Fig. 5, Table 2, Table 5)
We hypothesized that patients on HAART have lower levels of
integrated DNA than patients not on HAART. To test this hypothesis,
we measured integration levels in patients on HAART and off HAART,
averaged the integration level in each group, and performed a
Wilcoxon signed-rank test (Fig. 5, P=0.007). We found that there
was a difference between the proviral levels in the two groups:
patients on HAART had lower levels of integration than patients off
HAART (Fig. 5).
All the patients off HAART had a viral load N1000, except for
patient 11 with an unknown viral load (Table 5). All the patients on
HAART had an undetectable viral load the day of donation (Table 5)
except patients 4 and 5 who had barely detectable viral loads. BothTable 3
Positive Alu-gag signals are only detected in the chromosomal fraction of patient PBMC
DNA
Cycle number at which signal above threshold
Alu-gag (Ct) gag only (Ct)
Chromosomal 26.1±1.22 30.0±0.15
Linear HIV 29.6±0.11 29.9±0.07
Circular HIV 30.1±0.04 30.2±0.10
Mixture 26.8±1.76 28.6±0.11
The average Alu-gag and gag-only signals were determined in Fig. 4. Values in bold
indicate signals with detectable integration.populations had relatively preserved CD4 counts (≥290 cells/μl) (Table
5). Prior studies suggest that HAART treatment results in modestly
lower concentrations of viral DNA (Ngo-Giang-Huong et al., 2001;
Viard et al., 2004). We wanted to measure the amount of total DNA inIn this experiment, unintegrated HIV plasmid DNA was diluted in PBMC DNA,
integration standard DNA was diluted in PBMC DNA, and unintegrated and integrated
DNAwere mixed in a 100:1 ratio. From these, three samples of DNAwere prepared. The
ﬁrst sample contained 800 copies/reaction of unintegrated DNA (800 U). The second
sample contained 8 copies/reaction of integration standard DNA (8 IS). The third sample
was a mixture of 800 copies of unintegrated DNA and 8 integrated proviruses (800 U + 8
IS). Each sample was assayed 42 times using Alu-gag and gag-only PCR and the cycle
numbers at which the Alu-gag and gag-only signals were detected above the cycle
threshold are shown. Also shown are the number of proviruses calculated from the Alu-
gag signal for each sample. The standard curve used to calculate proviruses in this ﬁgure
is slightly different than the one generated in Fig. 2 and used to calculate the number of
proviruses for the patient samples because a different master mix was used for the
experiment in Table 4. All of the other experiments described in this paper used the
same master mix as was used to generate the standard curve in Fig. 2.
Table 5
Patient characteristics
Patient HAART
status
CD4
count
Viral load RU5 per 104
cells
Provirus 104
cells
RU5 per
provirus
1 ON 370 b400 12±1.8 0.66 18
2 809 b50 440±31 2.9 150
3 596 b50 25±3.7 2.2 11
4 745 400 32±3.8 3.0 11
5 515 57 61±12 2.5 24
6 461 b50 84±4.0 0.58 140
7 903 b50 200±6.1 0.55 360
8 749 b50 1.4±0.13 0.43 3.3
9 506 b75 14±0.32 3.0 4.7
10 322 b75 5.5±0.85 1.9 2.9
Average 87±43 1.8 72±37
11 OFF 290 Unknown 310±13 46 6.7
12 400 2.5×104 320±21 19 17
13 529 6.8×104 87±17 9.1 9.6
14 383 1.3×104 85±14 6.4 13
15 630 8.0×104 610±30 27 23
16 587 5.5×104 79±15 1.5 53
Average 250±86 18 20±6.9
The patient's HAART status, CD4 count, viral loads, total HIV DNA (RU5/10,000 cells±
standard error), and the ratio of total DNA to integrated DNA are shown for each patient.
Total DNA was measured using the primers and probe described in Fig. 1 without the
Alu-gag ampliﬁcation as described in the Methods.
Fig. 5. Patients on HAART have lower proviral loads in PBMCs than patients off HAART.
The average level of provirus in patients on and off effective HAART are shown with
their 95% conﬁdence intervals and are signiﬁcantly different by the Wilcoxon signed-
rank test (P=0.007).
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omitting Alu-gag pre-ampliﬁcation, wemeasured the level of total HIV
DNA. Consistent with prior literature, there is a signiﬁcant difference
in the level of total DNA (RU5) between the patients on and off HAART
(Table 5) as assessed by the Wilcoxon signed-rank test, P=0.02. We
also calculated the ratio of total DNA to integrated DNA in the two
patient groups. We found that HAART affected the level of integrated
DNA to a greater extent than the level of unintegrated DNA (Tables 2
and 5); however, larger numbers of samples need to be examined
before additional conclusions can be made about the ratio of
integrated to unintegrated DNA.
Discussion
Here we describe a new integration assay that is a signiﬁcant
advance over prior technology. Our improved kinetic PCR assay is
sufﬁciently sensitive to measure HIV integration and provide error
estimates in PBMC samples from infected individuals (Table 2).
Furthermore, results obtained with the assay suggest that the level
of integrated DNA is lower in patients on effective HAART than in
patients not on HAART. Although this result may seem obvious, two
prior reports failed to detect this difference (Carr et al., 2007; Ibanez et
al., 1999). Our ability to detect this difference suggests our assay may
be more precise than prior assays. Nonetheless, longitudinal studies
following the level of integration over time after HAART is initiated
will be required to determine the effect of HAART.
Our new integration assay overcomes the disadvantages of end-
point PCR, as well as the low sensitivity of prior kinetic PCR
techniques, by incorporating repetitive sampling and optimizing
conditions for rare event detection. Repetitive sampling increased
the sensitivity of the assay, permitted calculation of proviral numbers
and permitted calculation of conﬁdence intervals. Notably, prior
assays did not provide calculations of conﬁdence intervals. We further
optimized the assay by recognizing that we could sacriﬁce the range of
detection of integration to enhance sensitivity by increasing the
number of PCR cycles.
Prior to the development of our new assay, studies using endpoint
PCR assays to measure HIV integration in patient samples reported
several important ﬁndings (Chun et al., 1995; 1997a, 1997b; 1998;
Ostrowski et al., 1999) such as the level of integration, the concentra-
tion of proviruses in memory cells, and the failure of HAART to lower
the level of integrated HIV DNA in resting CD4+ T cells. However,
endpoint PCR has several disadvantages: it is semi-quantitative, labor
intensive, and does not permit calculation of conﬁdence intervals.
Our new assay can be used to expand upon the ﬁndings obtained
with endpoint PCR. Speciﬁcally, it can be used to reﬁne the initialestimates of the level of integrated DNA in several CD4+ subsets. Since
our assay is more sensitive, it should also provide proviral numbers in
cell subsets where integration was previously undetectable. In
addition, because our assay has tighter conﬁdence intervals, it can
be used to follow small ﬂuctuations in integration and so may be
useful in determining if HAART treatment leads to clearance of
integrated DNA from subsets of CD4+ cells.
To our knowledge, our integration assay is the most sensitive assay
currently available and the only assay that provides calculation of
conﬁdence intervals. Our measurements may also be more accurate
because we used a polyclonal integration standard. This standard
more closely models in vivo integration and was used to generate the
standard curve used to calculate proviral number in patient samples.
Nonetheless, we may be able to reﬁne our assay to make it more
accurate and more sensitive. For example, we are developing
mathematical models that will correct for the small signal that
unintegrated DNA contributes; although at most, the contribution
from unintegrated DNA results in a 2-fold overestimate in the number
of proviruses and only in a subset of patient samples with strong gag-
only signals. This correction is not likely required in our patients on
HAART because these patients show very little gag-only priming
(Supplemental Table). We speculate that little gag-only priming
occurs in some patients with relatively high levels of unintegrated
DNA (such as patients 2 and 7 on HAART) because the unintegrated
DNA may be discontinuous. This correction may be relevant for 3 of
the patients off HAART (such as patients 11,12, and 15) since therewas
signiﬁcant gag-only priming in these 3 patients (Supplemental Table).
This is the ﬁrst report that we are aware of that quantitates the
contribution from unintegrated DNA.
Application of our assay to larger numbers of patient samples may
address important issues in HIV pathogenesis. Even if the majority of
integrated proviruses are defective (Cofﬁn, 1995; Han et al., 2007;
Lassen et al., 2004, 2005), our ﬁnding that patients on HAART have
lower integration levels suggests that some populations of mono-
nuclear cells bearing proviruses can be cleared of provirus with
therapy and so should be monitored. In addition, with more precise
measurements of HIV integration, it is possible to test whether the
level of integrated DNA correlates with disease progression as has
been shown for viral RNA load (Mellors et al., 1995). It has been shown,
using kinetic PCR, that the level of total viral DNA within PBMCs also
84 J.J. Yu et al. / Virology 379 (2008) 78–86correlates weakly with disease progression (Kostrikis et al., 2002;
Ngo-Giang-Huong et al., 2001; Rouzioux et al., 2005; Viard et al.,
2004). With this assay, we could also measure the rate of decline of
integrated DNA in total PBMCs and evenwithin cellular subsets after a
patient begins HAART to assess the effect of therapy longitudinally.
It remains unclear why only a small fraction of CD4+ resting T cells
bearing integrated HIV DNA are latently infected, i.e. capable of
producing infectious HIV when stimulated (Cofﬁn, 1995; Han et al.,
2007; Lassen et al., 2004). Possible explanations are thatmany of these
cells bear proviruses that are either not transcribed, or do not produce
infectious virions when stimulated. Rigorous quantitation of the level
of integrated DNA, the frequency of cells capable of transcribing HIV
proviruses (Haase, 2005), and the frequency of cells capable of
producing infectious virions (Han et al., 2007; Lassen et al., 2004) may
give us a better understanding of latency. In addition, with the advent
of additional anti-HIV therapies, such as fusion inhibitors and
integrase inhibitors, it is now possible to treat patients with
intensiﬁed therapies. A sensitive assay for monitoring integration
levels may be an important tool for monitoring and quantitating the
additional beneﬁts of intensiﬁed therapy when viral load is already
undetectable.
Methods
Cell lines, plasmids, and viruses
The CD4+ T-lymphoblastoid cell line CEM-ss (Foley et al.,1965; Nara
and Fischinger, 1988) was maintained at 1–5×105 cells per ml. The
culture medium was RPMI 1640 supplemented with 10% heat-
inactivated fetal bovine serum, 25 mM HEPES, with 100 μg/ml
penicillin-streptomycin (Invitrogen Life Technologies). Virions pseu-
dotypedwith vesicular stomatitis virus protein G (VSV-G) (Blumenthal
et al., 1987; Emi et al., 1991) were collected 24 h after transfection of
293Tcells with pVSV-G (pHIT) (Fouchier et al., 1997) and pNL4-3Δenv/
GFP/HygR. The reporter virus was derived from pNL4-3, an X4-tropic
HIV clone (Adachi et al., 1986). The nef open reading frame (ORF) was
replaced with a green ﬂuorescent protein (GFP) and hygromycin
resistance cassette which contained an internal ribosome entry site
between the two ORFs. The plasmid (pNG38) was prepared by
removing the human genomic sequence from HXB-3 (Simon et al.,
1995, and personal communications with Nathan Gaddis).
Preparation of the Integration Standard (IS) cell line
The integration standard cell line (IS) was prepared as described
(Agosto et al., 2007). The standard contains diverse integration sites
with some integration sites close to an Alu repeat and others far away.
We estimated that about 10% of proviruses are detectable by our
methods at low proviral copy numbers (Fig. 2A).
Patients' blood samples
Patients on and off HAART therapy (both for at least three months)
were recruited using an IRB approved protocol to donate blood.
Patients 11, 12 and 13 were never on HAART. Patients 14, 15, and 16
were off HAART for 9, 4 and 7 years, respectively. Patients on HAART
had ≤400 copies of viral RNA/ml. PBMCs were prepared from
anticoagulated blood by Ficoll–Hypaque separation (Swiggard et al.,
2004). Total DNA was prepared (Blood and Cell Culture DNA Maxi Kit,
QIAGEN).
PCR conditions
Two step PCR ampliﬁcationwas performed as described (Agosto et
al., 2007; O’Doherty et al., 2002) with some modiﬁcations. Brieﬂy, the
ﬁrst ampliﬁcationwas performed on dilutions of the IS cells as well aspatient samples and no template controls. The sequence of the ﬁrst
step ampliﬁcation primers were: genomic Alu forward 5′ GCC TCC CAA
AGT GCT GGG ATT ACA G-3′ and HIV gag reverse 5′ GTT CCT GCT ATG
TCA CTT CC-3′. The gag primer is different from the previously
described primer (O’Doherty et al., 2002). It provides a better
consensus sequence than the original primer and provides more
efﬁcient Alu-gag ampliﬁcation. The IS was diluted in uninfected PBMC
DNA to keep the number of Alu sites per reaction constant. The
reactions were conducted in 50 μl: 10 mM Tris–HCl, pH 8.0; 1.8 mM
MgCl2; 1 mM mixed dNTPs; 100 nM Alu forward primer; 600 nM gag
reverse primer; and 0.05 units of Platinum Taq DNA polymerase/μl
(Invitrogen Life Technologies). The thermal cycler (DNA Engine PTC-
200, MJResearch) was programmed to perform a 2-min hot start at
95 °C, followed by 40 cycles of the following: denaturation at 95 °C for
15 s, annealing at 50 °C for 15 s and extension at 72 °C for 3 min 30 s
Linear, one strand ampliﬁcation (priming) was also monitored by
performing the ﬁrst ampliﬁcation PCR with the gag primer alone.
The second round real-time quantitative PCR was performed using
10 μl of the material from the ﬁrst ampliﬁcation. These were run with
an HIV-1 copy number standard (ACH-2) (Folks et al., 1989). The
sequences of the primers were: LTR (R) forward, 5′-TTA AGC CTC AAT
AAA GCT TGC C-3′; LTR (U5) reverse, 5′-GTT CGG GCG CCA CTG CTA
GA-3′. The LTR Taqman probes were labeled at their 5′ terminus with
the reporter ﬂuorophore 6-carboxyﬂuorescein (FAM) and at their 3′
terminus with the quencher tetramethylrhodamine (TAMRA). The
wild-type probe had the following sequence: 5′-FAM-CCA GAG TCA
CAC AAC AGA GGG GCA CA-TAMRA-3′ as described (Yun et al., 2002).
The two degenerate probes had the sequences listed in Fig. 1.
Reactions were carried out in a volume of 20 μl containing: 10 mM
Tris–HCl, pH 8.0; 75 mM KCl; 5.5 mM MgCl2; 500 nM carboxy-X-
rhodamine (ROX, Molecular Probes) as a passive reference; 1.2 mM
freshly added dNTPs; 250 nM LTR forward and reverse primers;
100 nM each Taqman probe; and 0.05 U of Platinum Taq DNA
polymerase/μl. The reactions were performed on an ABI7500 instru-
ment running 7500 Fast System SDS software with the following
thermal program: 20 s hot start at 95 °C, followed by 40 cycles of:
denaturation at 95 °C for 3 s, annealing and extending at 60 °C for 30 s
One step reactions were performed to measure the total HIV (RU5)
DNA by simply eliminating the ﬁrst Alu-gag ampliﬁcation step.
We constructed two degenerate probes, because two mutations
were relatively common. We found no difference in ampliﬁcation
efﬁciency of HIV integrated DNA in the presence or absence of the
degenerate probes (not shown).
The quantity of DNA was determined by OD260/280. The number of
genomes was calculated given that ~3.18×109 bp are present per
genome. These numbers were used to calculate the level of total and
integrated HIV DNA per cell.
Repetitive sampling to measure integration at low proviral copy number
Alu-gag PCR and gag-only PCRwere performed repetitively on 10 μl
aliquots of DNA at 2 μg/ml from patient samples and IS cells diluted in
uninfected PBMCDNA. Then HIV-1 speciﬁc kinetic PCRwas performed
on 10 μl aliquots of the ﬁrst reaction. After the kinetic PCR reaction, the
cycle thresholds (Ct) for each well were determined, i.e. the cycle
value where the accumulating ﬂuorescence (from ﬂuorescently
labeled amplicons) crossed a speciﬁed ﬂuorescent threshold value.
In all of the experiments described here, the ﬂuorescent threshold
value was set at 0.01 for data analysis. As previously shown (Agosto et
al., 2007), the average natural log of the cycle thresholds are linearly
related to the natural log of the proviral number. The standard
equationwas generated by ﬁnding the linear regression of the average
natural log of the cycle threshold values from each concentration of IS
and the natural log of the proviral number. The proviral number for
patient samples was then calculated using this standard curve. To do
this, the natural logarithm of each cycle threshold was obtained and
85J.J. Yu et al. / Virology 379 (2008) 78–86averaged and standard errors were calculated. These values (average
ln(Ct) ± standard error ln(Ct)) were entered into the equation
described in Fig. 2b. Because of the logarithmic transformation to
our data, the errors are asymmetrical for proviral numbers.
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